Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3008330 | 0.79 | CHRM2 (0.34) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3021865 | 0.76 | CHRM2 (0.38) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3012830 | 0.73 | CHRM2 (0.40) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL2021457 | 0.71 | CHRM2 (0.40) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3010100 | 0.69 | CHRM2 (0.36) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3020386 | 0.67 | PDK1 (0.38) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| (S)-Aceclidine SCHEMBL9146471 | 0.65 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| (R)-Aceclidine SCHEMBL9146752 | 0.65 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Aceclidine SCHEMBL121393 | 0.65 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL28431830 | 0.64 | CHRM2 (0.39) | CHRM2CHRM1MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2197882-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | Basf Se (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030649-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | TES, TRRAP, NAAA | CHRM2 3790/4885CHRM1 4053/4885MEN1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.